Enzyme prodrug cancer therapy selectively targeted to tumor vasculature and methods of production and use thereof
View Patent ↗Methods of treating cancer by targeting tumor vasculature using an enzyme prodrug cancer therapy treatment are provided.
1. A method of treating at least one of a cancer tumor and cancer cells in a patient wherein the cancer tumor/cancer cells is supplied by a tumor vasculature, comprising the step of:
contacting at least one blood vessel supplying a tumor in the patient with a therapeutically effective amount of a conjugate selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4, the conjugate comprising an annexin having an enzyme operatively attached thereto, wherein the annexin has the ability to specifically and stably bind to at least one of an external receptor and a binding site on an outer surface of a tumor vasculature endothelial cell, wherein the at least one of an external receptor and a binding site is specific to the tumor vasculature endothelial cell, and wherein the enzyme is able to convert a prodrug into an active drug, and whereby the conjugate is maintained on the outer surface of the tumor vasculature endothelial cell;
contacting the at least one blood vessel having the conjugate maintained thereon with a therapeutically effective amount of a selenomethionine prodrug, the selenomethionine prodrug comprising a substrate for the enzyme of the conjugate whereby the selenomethionine prodrug is converted into an active anticancer drug by the enzyme of the conjugate
in close proximity to the tumor vasculature endothelial cell, and wherein the active anticancer drug is carried across the artery wall and travels inside the tumor vasculature endothelial cell by diffusion and permeation flow and directly causes death of the tumor vasculature endothelial cell.
2. The method of claim 1 , wherein:
(a) the enzyme is conjugated to polyethylene glycol (PEG); and/or
(b) the conjugate is encapsulated in a liposome.
3. The method of claim 1 , further comprising the steps of:
administering a therapeutically effective amount of an immunostimulant to the patient, the immunostimulant selected from the group consisting of glycated chitosan; muramyldipeptide derivatives; trehalose-dimycolates; BCG-cell wall skeleton; various cytokines; and combinations and/or derivatives thereof, and wherein the immunostimulant is effective in enhancing the immune response of the patient to the tumor cells; and
administering a therapeutically effective amount of at least one chemotherapeutic agent to the patient.
4. A method of treating a patient having at least one of a cancer tumor and cancer cells wherein the cancer tumor/cancer cells is supplied by a tumor vasculature, comprising the step of:
administering to a patient a therapeutically effective amount of a conjugate selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4, the conjugate comprising an annexin having an enzyme operatively attached thereto, wherein the annexin specifically and stably binds to at least one of an external receptor and a binding site on an outer surface of a tumor vasculature endothelial cell of the patient, the at least one of an external receptor and a binding site being specific to the tumor vasculature endothelial cell, and wherein the enzyme is able to convert a prodrug into an active drug, and whereby the conjugate is maintained on the outer surface of the tumor vasculature endothelial cell of the patient;
allowing the free conjugate not bound to a cell to clear from the bloodstream;
administering an effective amount of a selenomethionine prodrug to the patient, the selenomethionine prodrug comprising a substrate for the enzyme of the conjugate, whereby the selenomethionine prodrug comes into contact with the conjugate in close proximity to the tumor vasculature endothelial cell and is converted into an active anticancer drug by the enzyme of the conjugate, and wherein the active anticancer drug is carried across the artery wall and travels inside the tumor vasculature endothelial cell by diffusion and permeation flow and directly causes death of the tumor vasculature endothelial cell of the patient.
5. The method of claim 4 , wherein:
(a) the enzyme is conjugated to polyethylene glycol (PEG); and/or
(b) the conjugate is encapsulated in a liposome.
6. The method of claim 4 , further comprising the steps of:
administering a therapeutically effective amount of an immunostimulant to the patient, the immunostimulant selected from the group consisting of glycated chitosan; muramyldipeptide derivatives; trehalose-dimycolates; BCG-cell wall skeleton; various cytokines; and combinations and/or derivatives thereof, and wherein the immunostimulant is effective in enhancing the immune response of the patient to the tumor cells; and
administering a therapeutically effective amount of at least one chemotherapeutic agent to the patient.